ImpactU Versión 3.11.2 Última actualización: Interfaz de Usuario: 16/10/2025 Base de Datos: 29/08/2025 Hecho en Colombia
Replacing procarbazine with etoposide in a new OEPA/COPE treatment scheme in children and adolescents with Hodgkin lymphoma: An evaluation of outcomes in the National Cancer Institute
LOPERA MARIN, John et al. Replacing procarbazine with etoposide in a new OEPA/COPE treatment scheme in children and adolescents with Hodgkin lymphoma: An evaluation of outcomes in the National Cancer Institute. rev. colomb. cancerol.[online]. 2015, vol. 19, n. 4, pp. 222-228. ISSN 0123-9015. https://doi. org/10.10167 j. rccan. 2015.11. 002. Purpose: Hodgkin's lymphoma (HL) has an age-standardised incidence of 5.3 cases per 100,000 population, and a cure rate of over 90% of cases. The prognosis depends on multiple
